Condition 1: chronic hepatitis B. Condition 2: Human Immunodeficeincy Virus. Chronic viral hepatitis B without delta-agent Chronic (viral) hepatitis B HIV disease resulting in haematological and immunological abnormalities, not elsewhere classified
Conditions
Interventions
This study has no control group.Only for those who are just entering the study, merely intervention is 0.5 cc of Hepatitis B vaccine in turn of zero and if required Repeat it one and six months later.
Diagnosis
This study has no control group.Only for those who are just entering the study, merely intervention is 0.5 cc of Hepatitis B vaccine in turn of zero and if required Repeat it one and six months later
Sponsors
Vice Chancellor of Hamadan University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Isolated HBC Ab positive patients who infected with HIV HBV DNA PCR positive, HBSAg positive, HBSAb positive Patients were excluded
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hbsab titer. Timepoint: pre and after vaccine, and repeated it in case of need. Method of measurement: quantitative serology. | — |
Secondary
| Measure | Time frame |
|---|---|
| Probable Complication of Hepatitis B vaccine. Timepoint: will be done during the study. Method of measurement: Will be Measured by observing and questioning the patients. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohammad Mahdi Majzoobi
Hamadan University of Medical Sciences
Outcome results
None listed